Exopharm is a world leader in the manufacture of exosome products.
- Exosomes have the potential to replace stem cells as medicines
- BioMAP external testing validates possible safety and mechanism of action
- Positive BioMAP testing provides a basis for further testing and future potential clinical trials
BioMAP testing of Exopharm’s exosome platform has validated safety and mechanism of action (MOA) and found that they have different and distinct activities compared to 4,500 other drugs. This confirms this therapeutic approach is a distinct and potentially new class of medicine.
Exopharm submitted its exosome products for testing under the BioMAP testing program operated by Eurofins, a European-based group of laboratories.
The headline results of the BioMAP® Diversity Plus® screen testing are:
Exopharm’s Plexaris product (exosomes from platelets) was compared with 4,500 experimental and sold medicines across a panel of 12 human primary cell-based systems. Plexaris was found to be safe (by comparison and absolute measures) and had notable biological activity in (i) tissue remodelling (ii) immunomodulatory and (iii) inflammatory-related activities.
Exopharm’s Cevaris product (exosomes from adult stem cells) was compared with 4,500 experimental and sold medicines across a panel of 12 human primary cell-based systems. Cevaris was found to be safe (by comparison and absolute measures) and had notable biological activity in (i) tissue remodelling, (ii) inflammatory and (iii) immune-modulatory-related activities.
“These are very positive results from a detailed external test of two of our experimental exosome products,” says Dr Ian Dixon, founder and CEO of Exopharm.
“The testing showed that both Plexaris and Cevaris had different and distinct activities to comparison drugs. This confirms our belief that exosomes are a distinct and potentially new class of medicine, different from existing medicines,” he adds. “Importantly, neither was shown to be cytotoxic, and neither caused antiproliferative effects at the concentrations tested.”
The BioMAP results “have a positive impact” across Exopharm’s business, and “will be of interest to potential partners,” Dr Dixon says. “Our testing is looking at issues of safety, mechanism of action and potency, and these results point to an expected safety profile and where these products could be best directed to serve patients.”
In summary, Dr Dixon says, the BioMAP results point to the potential value of Exopharm’s world-leading exosome products as medicines. Further testing is required to validate these products.
The BioMAP testing provides a basis for further non-clinical testing of Exopharm’s products in selected indications based upon improved MOA knowledge, based on the limitations outlined below.
“The results of the BioMAP testing will help Exopharm plan its next studies with additional insights and confidence. After that, further human clinical trials are the next step,” says Dr Dixon.
For further media information contact:
Dr Ian Dixon
Email: [email protected]
Phone: 03 9111 0026
Exopharm Limited is an Australian regenerative medicine biopharmaceutical company which is listed on the Australian Securities Exchange (ASX:EX1) seeking to develop and commercialise exosomes as therapeutic agents – initially a product called Plexaris™ and later a product called Exomeres™.
These products are exosomes that are derived from human platelets in relation to Plexaris, and adult stem cells in relation to Exomeres, and purified using the LEAP Technology and referred to as biologic products.
As its primary focus, Exopharm aims to be a leader in the field of human therapeutics using exosomes as regenerative medicine products for health span related conditions.
Dr Ian Dixon
P: +61 03 9111 0026